Effects of ERBB2 amplicon size and genomic alterations of chromosomes 1, 3, and 10 on patient response to trastuzumab in metastatic breast cancer

Genes Chromosomes and Cancer

Volumn 46, Issue 4, 2007, Pages 397-405

  Morrison, Larry E ^a   Jewell, Susan S ^a   Usha, Lydia ^b   Blondin, Beth A ^a   Rao, Ruta D ^b   Tabesh, Bits ^b   Kemper, Matthew ^b   Batus, Marta ^b   Coon, John S ^b  

^a Abbott Molecular Inc   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; TAXANE DERIVATIVE; TRASTUZUMAB;

AKT3 GENE; AMPLICON; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CENTROMERE; CHROMOSOME 10; CHROMOSOME 1Q; CHROMOSOME 3; ERBB2 GENE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENE LOCUS; GENE NUMBER; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOME ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; PIK3CA GENE; PRIORITY JOURNAL; PTEN GENE; PTGS2 GENE; SIGNAL TRANSDUCTION; TELOMERE; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 10; CHROMOSOMES, HUMAN, PAIR 3; FEMALE; HUMANS; NEOPLASM METASTASIS; RECEPTOR, ERBB-2;

EID: 33947189897     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20419     Document Type: Article

References (29)

1. Choi EM, Kwak SJ, Kim YM, Ha KS, Kim JI, Lee SW, Han JA. 2005. COX-2 inhibits anoikis by activation of the PI-3K/Akt pathway in human bladder cancer cells. Exp Mol Med 37:199-203.
2. Cobleigh M, Vogel C, Tripathy D, Mass R, Murphy M, Press M. 2001. Fluorescence in situ hybridization (FISH) may accurately select patients likely to benefit from herceptin monotherapy. Eur J Cancer 37:8190.
3. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ. 1999. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648.
4. Coon JS, Marcus E, Gupta-Burt S, Seelig S, Jacobson K, Chen S, Renta V, Fronda G, Preisler HD. 2002. Amplification and overexpression of topoisomerase IIα predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 8:1061-1067.
5. Di Leo A, Gancberg D, Larsimont D, Tanner M, Jarvinen T, Rouas G, Dolci S, Leroy J, Paesmans M, Isola J, Piccart M. 2002. HER-2 amplification and topoisomerase IIα gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 8:1107-1116.
6. Jacobson KK, Morrison LE, Henderson BT, Blondin BA, Wilber KA, Legator MS, O'Hare A, Van Stedum SC, Proffitt JH, Seelig SA, Coon JS. 2004. Gene copy mapping of the ERBB2/TOP2A region in breast cancer. Genes Chromosomes Cancer 40:19-31.
7. Jarvinen TA, Tanner M, Barlund M, Borg A, Isola J. 1999. Characterization of topoisomerase IIα gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 26:142-150.
8. Jarvinen TA, Tanner M, Rantanen V, Barlund M, Borg A, Grenman S, Isola J. 2000. Amplification and deletion of topoisomerase IIα associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 156:839-847.
9. Kauraniemi P, Barlund M, Monni O, Kallioniemi A. 2001. New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays. Cancer Res 61:8235-8240.
10. Khuri FR, Wu H, Lee JJ, Kemp BL, Lotan R, Lippman SM, Feng L, Hong WK, Xu XC. 2001. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 7:861-867.
11. Kiguchi K, Carbajal S, Chan K, Beltran L, Ruffino L, Shen J, Matsumoto T, Yoshimi N, DiGiovanni J. 2001. Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. Cancer Res 61:6971-6976.
12. Kundu N, Yang Q, Dorsey R, Fulton AM. 2001. Increased cyclooxygenase-2 (cox-2) expression and activity in a murine model of metastatic breast cancer. Int J Cancer 93:681-686.
13. Lebeau A, Deimling D, Kaltz C, Sendelhofert A, Iff A, Luthardt B, Untch M, Lohrs U. 2001. Her-2/neu analysis in archival tissue samples of human breast cancer: Comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 19:354-363.
14. Lehr HA, Jacobs TW, Yaziji H, Schnitt SJ, Gown AM. 2001. Quantitative evaluation of HER-2/neu status in breast cancer by fluorescence in situ hybridization and by immunohistochemistry with image analysis. Am J Clin Pathol 115:814-822.
15. Leng J, Han C, Demetris AJ, Michalopoulos GK, Wu T. 2003. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: Evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology 38:756-768.
16. Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, Slamon DJ. 2000. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 18:3651-3664.
17. Pauletti G, Godolphin W, Press MF, Slamon DJ. 1996. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13:63-72.
18. Pauletti G, Slamon DJ. 1999. Interphase cytogenetics of the HER-2/neu oncogene in breast cancer. In: Andreeff M, Pinkel D, editors. Introduction to Fluorescence In Situ Hybridization: Principles and Clinical Applications. New York: Wiley-Liss. pp. 153-171.
19. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ. 1998a. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16:2659-2671.
20. Pegram MD, Pauletti G, Slamon DJ. 1998b. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 52:65-77.
21. Persons DL, Bui MM, Lowery MC, Mark HF, Yung JF, Birkmeier JM, Wong EY, Yang SJ, Masood S. 2000. Fluorescence in situ hybridization (FISH) for detection of HER-2/neu amplification in breast cancer: A multicenter portability study. Ann Clin Lab Sci 30:41-48.
22. Press M, Mass R, Zhou J, Sullivan-Halley J, Villalobos I, Lieberman G, Flom K, Seelig S, Slamon D, Bernstein L. 2005a. Association of topoisomerase IIα (TOP2A) gene amplification with responsiveness to anthracycline- containing chemotherapy among women with metastatic breast cancer entered in the Herceptin H0648g pivotal clinical trial. Am Soc Clin Oncol Annu Meet Proc 23:9543.
23. Press M, Sauter G, Buyse M, Bernstein L, Guzman R, Santiago A, Ma Y, Eiermann W, Pienkowski T, Crown J, Robert N, Bee V, Taupin H, Villalobos I, Seelig S, Pegram M, Slamon D. 2005b. Topoisomerase IIα gene amplification as a predictor of responsiveness to anthracycline-containing chemotherapy in the Cancer International Research Group 006 clinical trial of trastuzumab (herceptin) in the adjuvant setting. Breast Cancer Res Treat 94 (Suppl 1):S54.
24. Roche PC, Suman VJ, Jenkins RB, Davidson NE, Martino S, Kaufman PA, Addo FK, Murphy B, Ingle JN, Perez EA. 2002. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 94:855-857.
25. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. 1987. Human breast cancer. Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182.
26. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. 2001. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792.
27. Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ. 2002. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: Evidence for involvement of AP-1 and PEA3. J Biol Chem 277:18649-18657.
28. Vadlamudi R, Mandal M, Adam L, Steinbach G, Mendelsohn J, Kumar R. 1999. Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene 18:305-314.
29. Vogel C, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ. 2001. First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: A preliminary report. Eur J Cancer 37 (Suppl 1):S25-S29.